Search results
Withdrawn from the market in 2009
- Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
en.wikipedia.org › wiki › Efalizumab
People also ask
How does Efalizumab work?
What happened to Raptiva (Efalizumab)?
Does Efalizumab have a long-term safety profile?
What happens if you take Efalizumab first dose?
Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.
Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
Dec 12, 2023 · Efalizumab is no longer available in the U.S. due to risk of progressive multifocal leukoencephalopathy (PML). Reactions to the first dose of efalizumab include headache, fever, nausea, and vomiting and are dose-level related, that is, the higher the dose the more likely are reactions.
Share. Post. Linkedin. [4/8/2009] FDA has been informed by Genentech, Inc., the sponsor of Raptiva (efalizumab), of their decision to initiate a voluntary withdrawal of Raptiva. The voluntary...
Nov 20, 2003 · After the discontinuation of efalizumab at week 24, an improvement of 50 percent or more in the psoriasis area-and-severity index was maintained in approximately 30 percent of subjects during the...
- Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott Glazer, Naji H. Tawfik, Pat...
- 2003
Efalizumab (Raptiva, anti-CD11a) is a humanized form of a murine antibody directed against CD11a, the α subunit of LFA-1. In vitro studies demonstrated that by binding to CD11a, efalizumab inhibits multiple key pathogenic steps: T cell activation, 7. cutaneous T cell trafficking, 8. and T cell adhesion to keratinocytes. 7.
To assess the long-term safety profile of efalizumab, data were analyzed to identify possible risk factors for adverse events (AEs) and serious AEs (SAEs), including prespecified comorbid conditions and concomitant medications. Results: Observation of patients started in May 2006, and as of January 2008, 217 patients have been enrolled.
